Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis.
Nishio T, Koyama Y, Liu X, Rosenthal SB, Yamamoto G, Fuji H, Baglieri J, Li N, Brenner LN, Iwaisako K, Taura K, Hagood JS, LaRusso NF, Bera TK, Pastan I, Brenner DA, Kisseleva T.
Nishio T, et al. Among authors: li n.
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2101270118. doi: 10.1073/pnas.2101270118.
Proc Natl Acad Sci U S A. 2021.
PMID: 34253615
Free PMC article.